anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
New formulas of Iron oxides nanoparticles capped with a mixture of multivitamins such as folic acid, Nicotinic acid (vitamin B9) and Ascorbic acid (vitamin C) has been developed for the rapid and efficient treatment of life threatening iron-deficiency anemia. Small single dose of iron oxides-multivitamin nano-composite as low as 25 mg elemental iron per does is sufficient to increase the hemoglobin level from 4.4 g/dl up to 14.6 g/dl within only four days after administration. The multivitamin which used in this nano-composite enhances iron absorption significantly and elevated the concentration of hemoglobin. Two dosage forms of Iron nano-composites have been developed, gel capsules and aqueous solution for oral administration. Animal trials studies reveal that introducing single dose of Iron Oxide- vitamin nano-composites containing 2.57 mg elemental iron per kg rat body weight (equal to 25 mg in human) is sufficient to correct the hemoglobin level and cure Anemia via oral administration. The toxicity study reveals that the LD50 of our new iron nano-composite is 1425.3 mg/kg rat body weight, means that the LD50 of nano-sized iron nano-composites in standard human (60 kg weight) is 13,854 mg. Thus, the single dose required for rapid treatment of iron deficiency anemia is 554 times less than the LD50 in human. No apparent of any sight of toxicity on hematological, biochemistry or histopathology studies. Moreover, the histopathology study of the bone-marrow suggests that the used iron oxides -vitamin nano-composites increase the number of the RBCs precursors which stimulate the bone- marrow to produce more RBCS.
Among the physiological systems most important to brain development in emerging adulthood is the endocannabinoid system, which among other roles facilitates cognitive and behavioral processing, including the underpinnings of stress management and resiliency. Sex differences in endocannabinoid system development have been identified, and emerging evidence indicates a bidirectional relationship between stress exposure and the endocannabinoid system during emerging adulthood. Repeated exposure to exogenous cannabinoids, such as those administered via cannabis use, perturbates endocannabinoid system development, which may adversely affect the programming of future coping in a manner that differs by sex. Use of cannabis, which exerts its psychoactive effects via delta-9-tetrahydrocannabinol binding to endocannabinoid receptors, is more common among emerging adults than in any other age group. Many regular users develop a maladaptive, impairing pattern of use characterized as cannabis use disorder (CUD). A constellation of preliminary evidence suggests several factors disproportionately complicate CUD in females compared to males; the salience of these factors in emerging adulthood indicates that this developmental stage deserves focused sex differences research to inform clinical management. A central running thread is the importance of stress and stress-reactivity across endocannabinoid system development, cannabis use, CUD, cannabis withdrawal, and relapse to cannabis use. This study combines rigorous ecological momentary assessment (EMA), controlled human laboratory procedures, and innovative bioassay collection. Emerging adult cannabis users with CUD (ages 18-25, N=148, 1:1 female to male ratio) will undergo 3 days of reinforced abstinence with EMA monitoring of cannabis withdrawal and stress-related symptoms, followed by a standardized laboratory stress induction paradigm. Blood levels of endocannabinoid system markers will be assessed before and after the abstinence period; during the lab session, self-report measures and biomarkers of stress reactivity will be collected. Double-blind cannabidiol (CBD) versus placebo dosing before the laboratory stress paradigm will allow for examination of effects on stress response during withdrawal. Prior work indicates CBD administration reduces stress response in general populations and preliminary research suggests this effect may extend to cannabis users; this has not been rigorously applied to induced stress amid cannabis withdrawal in emerging adults with CUD, a context particularly important for females with CUD who often report using cannabis to cope with stress. Following the laboratory session, EMA monitoring will resume as participants return to ad libitum cannabis use, providing the opportunity to test associations between stress reactivity and time to resumption of use. The proposed study is designed to elucidate sex differences and guide the development of tailored treatments that address factors disproportionately affecting emerging adult females with CUD.
Macro-agglomerate title composn. is prepd. by treating a sulphur cpd. such as hyposulphite with an acid in the presence of Tc-99m to give a colloid, adding denatured albumin (pref. normal serum albumin in the first stage of denaturation), adjusting the pH to the isoelectric pt. of the protein to form agglomerates, which are heated to produce uniform particles of the required size, pref. 10-100 mu. 75 - 100% localises in the lungs, very little in the liver and the prepn. clears the lungs after 4-24 hrs. It is intended that the material is prepd. immediately before use.
Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100 mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.
FIELD: medicine, oncology. SUBSTANCE: method involves the use of the following preparations: semicarbazide hydrochloride, urea, cadmium halides at mass number 113. Additionally, stable isotopes of gadolinium can be used, in part, its oxides at mass number 155-157. Also, glucine is used in combination with urea and sodium hydrocarbonate that enhances urea penetration in tumor cells. EFFECT: enhanced effectiveness of treatment and immunity capability of patient. 4 cl
This new IMN 1207 study is a follow-up study to the first IMN 1207 trial which was sponsored by Immunotec Inc during the last 3 years. The study revealed that the cysteine-rich whey protein isolate formulation IMN 1207 caused a significant reversal of weight loss (P \<0.05) and a conspicuous increase in survival. The outcome of the first IMN 1207 study has been published in (Tozer RG, et al. Cysteine-Rich Protein Reverses Weight Loss in Lung Cancer Patients Receiving Chemotherapy or Radiotherapy. Antioxid Redox Signal. 2008 Feb; 10(2):395-402). PMID:18158761.

The purpose of this IMN 1207 follow-up study is to confirm the effect of a cysteine-rich non-denatured whey protein isolate formulation IMN1207 (20g daily) versus casein (20 g daily) on the reversal of weight loss (cancer-related wasting) over a 40 week treatment period in non-small cell lung cancer subjects with or without conventional therapy, i.e., chemotherapy or radiation. In addition, it is prospectively designed to test the hypothesis that, IMN1207 versus casein over a period of 66 weeks observation period which includes a 6 months follow-up period, increases the survival of these subjects. Also, the effect of IMN1207 on the quality of life in a defined subgroup of subjects will be determined.
INTRODUCTION: Patients' and surgeons' perceptions of cutaneous scarring can vary, causing unpleasant physical and psychological outcomes. This study aims to bridge the current scientific literature gap and understand the impact of patient-perceived scar cosmesis after anterior and posterior cervical spine surgery.
METHODS: Retrospective review of patients ≥18 years old who underwent anterior or posterior cervical spine surgery from 2017 to 2022 at a large, urban academic group. To select patients with adequate time for surgical scar maturation, only patients who were greater than 6 months postsurgery were included. The Scar Questionaire Survey (SCAR-Q) survey, a surgical scar assessment tool, was administered to patients to assess patient perceptions of scar symptomatology, appearance, and psychosocial impact. Scores range from 0 to 100, with 100 as the best outcome. An additional 5-item Likert scale question was administered to assess overall surgical satisfaction.
RESULTS: All 854 respondents who completed the survey were stratified into 2 groups "Unsatisfied vs. Satisfied." Patients who were "unsatisfied" with their surgery had the lowest outcome scores for SCAR-Q appearance, symptom, and psychosocial scores than those who were "Satisfied" (P < 0.001). Females had significantly "higher/more favorable" responses for SCAR-Q Appearance (77.5 vs. 82.8 P < 0.001) and Psychosocial (87.4 vs. 94.3 P < 0.001) scores compared to males. Regression analysis performed for each component score showed that increases in all 3 component scores were significant in patients in the satisfied group.
CONCLUSIONS: Our study demonstrates that cervical spine surgery patients unsatisfied with their surgical outcome have lower scar-related scores, highlighting the impact of cosmetic closure and appearance.
PURPOSE: A composition containing a Zinnia elegans extract for preventing or treating BSE(bovine spongiform encephalopathy) is provided to suppress abnormal prion, and to be used as an eco-friendly preservative or therapeutic agent for BSE. CONSTITUTION: A veterinary composition for preventing or treating BSE contains a Zinnia elegans extract. The extract is prepared using a solvent selected from a group consisting of water, C1-C4 alcohol, and a mixture thereof. The concentration of the extract is 12.5 microgram/ml. A feed additive composition for preventing or treating BSE contains the extract. A feed composition for preventing or treating BSE contains the extract.
Background: Familial exudative vitreoretinopathy (FEVR) is a rare hereditary disorder of the retinal vasculature characterized by abrupt cessation of the growth of peripheral retinal capillaries. FEVR seems to exhibit significant phenotypic and genotypic variability but since this is a rare disease the clinical and genetic characteristics of the disease have not been extensively studied so far. Correlation of phenotypes with certain genotypes have not been made yet. Clinical findings can vary from very mild disease with only subtle changes of the peripheral retinal vasculature without symptoms to severe disease with retinal neovascularization, retinal exudates, vitreoretinal adhesions, peripheral vitreous opacities, retinal folds and tractional retinal detachment. The condition remarkably resembles retinopathy of prematurity but affected patients do not have a history of prematurity or supplementary oxygen use.

The disorder is usually inherited as an autosomal dominant trait but few families show x-linked or autosomal recessive inheritance. A significant number of patients with autosomal dominant FEVR show linkage to 11q13-q23 (EVR1). Two genes in this locus have recently been shown to be associated with the disease. FZD4, the gene that encodes for Frizzled-4, the Wnt receptor, is one of them. It has been estimated by recent studies that 20-30% of patients with autosomal dominant FEVR show mutations in FZD4. LRP5 (low-density-lipoprotein receptor-related protein 5), a Wnt co-receptor, was recently shown to be mutated in approximately 15% of cases. One large autosomal dominant pedigree has shown linkage to 11p13-p12 locus (EVR3) and this gene has not yet been identified. It now becomes obvious that more genes are associated with the autosomal dominant type of the disease. Most of the patients with the x-linked type have mutations in the Norrie disease gene (EVR2). The autosomal recessive form of the disease is much rarer and linkage studies have not yet been performed.

Aims: The objectives of this protocol are to study the clinical characteristics of FEVR, and also to assist in identifying the location and sequence of corresponding genes. Since one of the genes so far identified, LRP5, is also causing the osteoporosis-pseudoglioma syndrome, an inherited disorder with severe osteoporosis, we would also like to know if FEVR patients, especially those with mutations in LRP5 also have some degree of osteoporosis. Localization and identification of the responsible gene will help us understand the pathogenesis of FEVR and possibly the mechanism of retinal angiogenesis and lead to potential treatments.

Methods: Patients as well as available family members are to be evaluated by physical examination and fluorescein angiography, in order to clinically characterize the inheritance pattern in each family. Blood will be obtained by all participating subjects for the molecular studies.
PURPOSE: To obtain the subject solution containing a physiological amount of an electrolyte and an amino acid mixture having a specific composition as a permeating substance and administrable over a long period without causing the complication in microbial system or intraperitoneal dialysis. CONSTITUTION: This dialytic aqueous solution or rinse solution contains a physiological amount of an electrolyte and amino acids in amounts shown in the table. The ratios of isoleucine:leucine:valine are 1:1.5:2.5 and the ratio of tyrosine:phenylalanine is 1.25:1. The solution may further contain other additives. The content of the amino acid mixture in the solution is 2-50g/l, preferably 7.5-12.5g/l. The solution preferably has an osmotic pressure of 300-700mosm/l, especially 320-550mosm/l and a pH value falling in acidic range, especially 5.5-6.5.
OBJECTIVE: Churches are frequently used to reach Black adults to effect weight loss. However, there has been no recent review, to our knowledge, inclusive of solely Black adults in church settings. We sought to comprehensively examine the methodological approaches and weight-loss outcomes of church-based weight-loss lifestyle interventions conducted among Black adults to provide insights on literature gaps and offer suggestions for future research.
METHODS: Google Scholar, PubMed, and CINAHL (Cumulative Index to Nursing and Allied Health Literature) were searched for trials conducted in churches that reported weight outcomes at any time point. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guided manuscript development.
RESULTS: A total of 15 studies (N = 2285) from 2007 to 2023 met inclusion criteria, and 33% were high-quality randomized trials. The majority were pilot studies (60%) conducted in the Southern United States. Most reported significant postintervention weight loss. The follow-up time points varied from 2 to 12 months. Methodological approaches included the following: cultural adaptations (93%); theory-guided (93%); delivered by community health workers (80%); and delivered in person in a group format (100%). Only one study offered individual-level attention beyond texts/emails. Most participants were well-educated female individuals.
CONCLUSIONS: Weight-loss interventions among Black church settings effect statistically significant weight loss, albeit in a small way. Limitations include pilot studies and small samples. More rigorously designed studies are warranted.
PURPOSE: To make determination of an effect in a cancer treatment by implanting a sealed fiber segment in which tumor cells are sealed within a segment of semi-permeable hollow fibers, thereafter treating a mammal by a cancer treating method and then assaying an effect of the cancer treating method for cells in the hollow fiber segment. CONSTITUTION: A tumor material in a suspension 16 is filled in a hollow fiber segment and then both terminals thereof are fixed with a hemostatic forceps for sealing, to obtain a filled fiber segment 10. Then, the fiber segment 10 is implanted in a rat 18. Thereafter, a cancer treatment such as chemotherapeuticagent, immunotoxin, biological controller and so on is carried out. Then, an effect of the cancer treatment for cells in the hollow fiber is assayed. Thereby, the effect of the cancer treatment can be determined.
Enrolled patients will receive three doses of neoadjuvant pembrolizumab (200 mg administered as an intravenous infusion over 30 minutes every 3 weeks). The first dose of pembrolizumab will be administered approximately 14 days prior to initiating radiotherapy. The second dose will be administered three weeks later (week 1 of chemoradiation). The third dose will be administered 3 weeks later (week 4 of chemoradiotherapy). Pembrolizumab will be given every 3 weeks and may be given at the same time as systemic therapy. All patients will receive radiation treatment (45Gy in 25 fractions at 1.8 Gy/fraction) using image-guided radiation therapy with concurrent, weekly carboplatin (AUC 2) and paclitaxel (50mg/m2 of BSA). Restaging will be performed per standard of care approximately 4-8 weeks after completing chemoradiotherapy. Resection will be performed approximately 6-12 weeks after completing chemoradiotherapy per standard of care. Postoperatively, three additional cycles of pembrolizumab (200 mg every 3 weeks) will be administered as adjuvant therapy.
The present invention provides an effective component of Chinese medicine cortex moutan and a preparation method. The active components are 15 to 35% of peonol glycoside and 30 to 50% of tree peony bark glycoside b. The preparation method for the effective component comprises the steps that after being pulverized, the cortex moutan is heated and extracted, concentrated liquid is extracted into extract, and the extract is dissolved; the cortex moutan is separated by an ODS-C18 column, and after eluent is concentrated and dried, a sample is obtained; the obtained effective component is continuously separated by preparative liquid chromatography and prepared into the medicinal preparation by adding medicinal additives according to a preparation method allowed in pharmacy. The preparation method of the present invention uses a positive silica gel column which can effectively remove impurities, such as sugar, proteins, amino acid, etc., and thus, the content of effective components is increased; simultaneously, the preparation method adopts the preparative chromatography and can quickly and accurately obtain the effective components. The effective component of the cortex moutan, provided by the present invention, can protect patients with myocardial ischemia and has simple and specific chemical components. The quality of medicines is much easier to control in the process of preparation, and the effective component of the cortex moutan can be applied to the preparation of medicines for treating and preventing cardiovascular diseases.
The present invention discloses a new purpose that embryonic ribonucleic acid (RNA) of fowls can be used as a new medical product. The embryonic ribonucleic acid (RNA) of fowls has the action and the purposes of cancer resistance, immunological function enhancement and aging resistance. In addition, the embryonic ribonucleic acid (RNA) of fowls has main physical and chemical detection standards that the molecular weight of RNA is larger than or equal to 5000; the embryonic ribonucleic acid (RNA) of fowls is suitable for a protein reaction (1) and a sulfosalicylic acid method and has the advantages of no pyrogen, no allergy, no stimulation, no pathogen and no toxic or side effect. Every 1 ml of injection of the preparation contains more than 250 micrograms of RNA, and the preparation can be used for hypodermic injection, intramuscular injection and intravenous injection. The embryonic ribonucleic acid (RNA) of fowls can directly kill cells, has the cancer-killing efficacy of inducing LAK cells and activating NK cells and the certain action of aging resistance and can obviously enhance the immunological functions. The embryonic ribonucleic acid (RNA) of fowls has the advantages of rich and stable sources of the raw material, less preparation investment, simple preparation technology, easy large-scale production and good market competitiveness.
Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IB, patients will have standard of care neoadjuvant chemotherapy or pre-operative radiation therapy during the time that the OxyChip is within the tumor, which is typically 6 weeks but may be up to 52 weeks.
1377674 Tetracycline complex; piperazine biguanide-formaldehyde compound SPA-SOC PRODOTTI ANTIBIOTICI SpA 22 June 1973 [11 July 1972] 32367/72 Heading C2C A novel complex of equimolar amounts of tetracycline, formaldehyde and piperazine biguanide is prepared by reacting the component substances with each other, or by reacting (i) a piperazine biguanide-formaldehyde reaction product with tetracycline or (ii) a piperazine biguanide-tetracycline reaction product with formaldehyde. The reaction may be performed in a solvent (e.g. methanol or ethanol) at about 5-30‹ C. The said complex may be salified with one or two equivalents of an organic or inorganic acid to give a mono- or di-acid addition salt. Preparation of the intermediates referred to in (i) and (ii) above viz. a 1: 1 piperazine biguanide-formaldehyde compound, and a 1 - 1 piperazine biguanide-tetracycline compound) is described. Also the preparation of piperazine biguanide free base by treatment of the bihydrochloride salt with methanolic NaOH is described. The novel complexes and their salts may be admixed with a pharmaceutical carrier to provide antibiotic pharmaceutical compositions.
Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.
There have been over 769 million cases of COVID-19, and up to 50% of infected individuals are asymptomatic. The purpose of this study aimed to assess the use of a clinical-grade physiological wearable monitoring system, ANNE One, to develop an artificial intelligence algorithm for (1) cough detection and (2) early detection of COVID-19, through the retrospective analysis of prospectively collected physiological data from longitudinal wear of ANNE sensors in a multicenter single arm study of subjects at high risk for COVID-19 due to occupational or home exposures. The study employed a two-fold approach: cough detection algorithm development and COVID-19 detection algorithm development. For cough detection, healthy individuals wore an ANNE One chest sensor during scripted activity. The final performance of the algorithm achieved an F-1 score of 83.3% in twenty-seven healthy subjects during biomarker validation. In the COVID-19 detection algorithm, individuals at high-risk for developing COVID-19 because of recent exposures received ANNE One sensors and completed daily symptom surveys. An algorithm analyzing vital parameters (heart rate, respiratory rate, cough count, etc.) for early COVID-19 detection was developed. The COVID-19 detection algorithm exhibited a sensitivity of 0.47 and specificity of 0.72 for detecting COVID-19 in 325 individuals with recent exposures. Participants demonstrated high adherence (≥ 4 days of wear per week). ANNE One shows promise for detection of COVID-19. Inclusion of respiratory biomarkers (e.g., cough count) enhanced the algorithm's predictive ability. These findings highlight the potential value of wearable devices in early disease detection and monitoring.